Hence, we sought to evaluate the function of FGFR4 in ccRCC, with a focus on its direct effects on tumour cell proliferation and the potential of selective pharmacological FGFR4 inhibition as a therapeutic strategy. This evidence concerns the gene FGFR4 and nonpapillary renal cell carcinoma.